OmniAb, Inc. (OABI) Earnings Call Transcript & Summary

August 6, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 47 min

Earnings Call Speaker Segments

Kurt Gustafson

executive
#1

Thanks a lot, operator, and good afternoon to everybody. We appreciate all of you taking the time to be with us on this conference call covering the financial results for our second quarter of 2026. Slides have been prepared to go along with the prepared remarks we'll be making today, and you can find those in the Investors section over at our website, omniab.com. Prior to getting started, I want to remind those listening that remarks made on this call by OmniAb's management will contain forward-looking statements as defined under the federal securities laws; such forward-looking statements carry risks and uncertainties that might lead actual results to differ materially from any results that are anticipated. These forward-looking statements are subject to the cautionary statements laid out in today's press release as well as our SEC filings. It's important to note that this conference call includes time-sensitive information that is accurate only as of the date of the live broadcast, which is today, August 6th, 2026. Unless the law requires otherwise, OmniAb assumes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances occurring after the date of this call. Joining me this afternoon is Matt Foehr, who serves as OmniAb's President and CEO, along with Amechi Nwachuku, our Chief Operating Officer, who was recently appointed to that role. On today's call, Matt will go over some business highlights, I will review our Q2 financial results and provide an update to our full-year guidance, and after that we'll open things up for questions. With that said, I'll hand the call over to Matt.

Matt Foehr

executive
#2

Thank you, Kurt. Hello, everyone, and good afternoon. We appreciate you being here for our Q2 call. I'll begin on slide four. Momentum remains evident in our operations, as the second quarter delivered robust results, driven by progress across our partnered program portfolio. At OmniAb, we've structured the business to gain from revenue streams that are both long-lasting and reliable. It's exciting to share that programs built on our distinctive discovery platforms keep advancing into clinical trials and are moving forward through later phases of development. This movement through the clinic provides clarity regarding the worth that can be unlocked as our pipeline grows more mature and as a rising count of partnered initiatives hit key milestones and get closer to possible royalty income. Innovative platforms we've developed strengthen the role we play as an essential licensing collaborator in enabling technology, and they bolster partnerships we already have as well as ones we're just forming. Being equipped with unique, differentiated technology and the skills we bring means we remain leaders in discovering what comes next, which lets us generate substantial worth for our stakeholders and for the wider industry. It's a pleasure to report that the two most recent technologies we brought to market for generating antibodies — OmniUltra and OmnidAb — are creating fresh markets and significant new possibilities for our company. Programs originating from our chicken-based technologies are increasingly advancing into clinical trials. Turning to xPloration, two instruments were sold in the quarter, and we keep laying a very solid groundwork for that portion of our operations. From our perspective, xPloration represents a significant chance to extend our market reach, bring in additional revenue sources, and create more value both for our stakeholders and for our customers. The conversations we continue to have with partners, some market research conducted quite recently, and a pipeline that keeps expanding with strong prospects who are assessing the xPloration system for their own labs — all of this makes us more and more confident about how large this market opportunity could be. We're also genuinely thrilled to have Amechi joining the team; this person is a seasoned global executive with deep experience, and will help steer and expand the business. And finally, the steady momentum we're seeing across our partner programs has us feeling good, since it produced yet another very solid quarter for us. For 2026, we're lifting our full-year financial guidance once more — bumping up the revenue figure along with the cash projection. Those two metrics, in our view, matter a lot: they signal the worth built into a partnered-program portfolio that keeps expanding and carries contracted downstream economics. Kurt is going to walk everyone through the revised guidance numbers in more depth when he gets up to talk. I want to pause as well and call attention to how our platform keeps widening, since the innovation engine inside it is pushing forward novel technologies that, we think, set us apart even more and reinforce what we offer. Our partner ecosystem is expanding too, and it keeps us tuned in to what those partners are currently doing and what they intend to do next. Beyond that, it provides us with a distinctive perspective on what the industry requires on a wider scale. We make use of that perspective as we keep improving our technologies, our workflows, and our capabilities. On slide number five, I'd like to call attention to xPloration. xPloration broadens our scope of work and complements our novel antibody generation technologies effectively. This platform is our proprietary high-throughput single B-cell screening system, and it employs machine learning along with artificial intelligence. The offering includes a competitively priced instrument, proprietary single-use consumables, and annual software subscriptions as well as maintenance contracts. So there's potential for several revenue streams for our business; during Q2 we hit a significant milestone by selling two instruments, and robust commercial interest keeps growing our sales pipeline. Initial feedback points to xPloration's fast runtimes, user-friendliness, and general robustness. With all these advantages for users in mind, we have strong conviction that our technology is both the correct one and arriving at the correct moment. Our partners and the broader industry are increasingly recognizing the importance of lab automation, as well as instrumentation that delivers high value and high impact, for producing proprietary data at a large scale and for screening and selection assisted by AI and ML. Our excitement about what this technology can deliver to the business remains very high, and we look forward to sharing additional details with you at the Investor and Analyst Day taking place October 6th, which I will touch on more in a moment. I'll now turn to some of our metrics, starting with slide number six. As of the end of the second quarter, we had 110 active partners. In the second quarter, we signed new licensing deals with EnRosa Therapeutics and argenx. The argenx one is especially notable—they're a worldwide leader with a deep track record of pioneering R&D, and they talk about "leading a new era of innovation in immunology." We think our technologies line up nicely with some of what they're trying to achieve in discovering new drugs. Across the rest of our partner base—discovery-stage businesses, big pharma, and academic groups—the mix remains nicely balanced. A majority of those partners are based in the U.S., with the remainder concentrated largely in Europe and Asia. Another point of pride for us is that OmniAb still counts eight of the world's 10 biggest drugmakers as active partners — in our view, that speaks to how solid and high-caliber our partner roster is, and it gives further evidence of what our technology platforms are worth. Moving to slide number seven, you'll find our active programs metric there; we closed out the quarter with 425 active programs, and that gain reflects a mix of new program starts or additions alongside the normal attrition that occurs when partners adjust their pipelines and priorities. Importantly, about 98% of the programs we have active come with contracted future economics owed to OmniAb. Looking at everything we have across our portfolio, the total sits above $3 billion when it comes to contracted potential milestone payments tied to standard antibody licenses, and the contracted royalty rate averages out to roughly 3.4%. Moving over to the clinical picture, our partners' active clinical programs along with approved products appear on slide number eight. By the close of Q2, our technologies were being used by 34 active clinical programs and approved products. That number captures both programs newly entering the clinic and those lost along the way. During 2026 so far, we've added 4 more clinical entrants, and we anticipate that additional ones will continue to come in. Within these ongoing clinical efforts, since the start of the year we've seen meaningful clinical progress, and further favorable movement is what we expect in the months to come. I want to flag that OmniAb still owes us about $340 million in potential milestone payments that are under contract and linked to these clinical-stage programs that are currently active. Also, as you can see on the slide, there are 6 programs right now in phase I or phase II trials, and every one of them stems from our genetically engineered chicken antibody discovery technologies, which are OmnidAb and OmniChicken. I think it's important to note that no other company anywhere in the world aside from OmniAb has a transgenic chicken platform that can produce fully human antibody sequences. When you compare mammals, a large number of therapeutic targets have historically been highly conserved, or their sequences are fairly similar, and that makes the value proposition for our transgenic chickens even stronger. One element of what makes a chicken platform advantageous stems from how far apart, evolutionarily speaking, a chicken sits as a biological host for discovery compared with other animals — mammals in particular. That evolutionary gap enables our chickens to generate a strong response along with a varied collection — a library, so to speak — of antibodies aimed at novel targets that a mammal, or other methods, most likely could not.

Matt Foehr

executive
#3

We possess multiple categories of genetically modified chickens capable of generating distinctive antibody repertoires, assisting in the discovery of medicines including traditional heavy and light chain antibodies, common light chain formats, single domain antibodies, ultralong CDRH3 domains, dual modality antibodies, and at this point even peptides. Such abilities unlock marketplace possibilities and are fueling partner curiosity. We're observing growing curiosity regarding our engineered chicken platforms, and at this point, with additional clinical validation, we believe that could generate still more curiosity. Moving to slide nine, this visual encapsulates our clinical and commercial stage partner pipeline for active programs that carry downstream economics to OmniAb. Any program's position here reflects its most advanced stage in any geography or in any indication. Looking at the pipeline, you can likely tell that things have shifted quite a bit in the later stages of development. We now have more programs sitting in phase I, phase II, and phase III, and a handful of bigger events landed during Q2. Two programs in particular jumped all the way from phase I to phase III in Q2: Ramantamig, J&J's trispecific antibody targeting multiple myeloma, and Merck KGaA's precemtabart tocentecan, a CEACAM5-ADC aimed at colorectal cancer. Also worth flagging is Boehringer Ingelheim's BI 878 program, which shows up in phase II on this pipeline. BI is going after a MASH indication — a sizable market and a serious health challenge. On the right side of this graphic, you'll see an ever-growing list of what many of our partners consider promising candidates that could be either first-in-class or best-in-class treatments. Now I'd like to move to slide 10 and call out several recent developments that are significantly contributing to momentum in parts of the business. In particular, we're happy to point to ongoing progress within our partners' clinical programs. I'm going to move around this slide a little. I want to point out the Merck KGaA program—Merck has announced that, on the basis of phase I data, it's now in a phase III trial with precemtabart tocentecan. That's the possible first-in-class investigational anti-CEACAM5 antibody-drug conjugate being developed to treat metastatic colorectal cancer. The data they reported were quite strong, and this slide also sums that up. I also want to call attention to TEV-'408, the anti-IL-15 asset, which drew considerable news earlier in the year when Royalty Pharma made a big investment in that program. Teva has now shared that it intends to kick off a phase II-B trial in vitiligo during the fourth quarter, after seeing positive results from prior clinical testing. According to those clinical findings, patients with either active or stable vitiligo experienced gains in skin pigmentation. Among evaluable participants at week 24, close to 75% of patients said their facial vitiligo had gotten better, and half of them described it as much improved or very much improved. On the left side of this slide, as you can see, Immunovant reported clinically meaningful response rates at week 16 for IMVT-1402 in its trial involving rheumatoid arthritis patients who are difficult to treat. Additional updates on this program are anticipated from Immunovant during the latter half of this year, and in that same latter half, an update regarding IMVT-1402 in lupus is also expected from Immunovant. Moving now to slide 11, we are eager for several thrilling developments in the latter half of this year, with further anticipated readouts from Teva as well as updates concerning the IMVT-1402 program at Immunovant. Progress updates were likewise shared earlier this morning, noting that across all 6 of the announced indications being pursued, the IMVT-1402 program continues to remain on track. Before I turn things over to Kurt to walk through our second-quarter numbers and the updated outlook we're giving for 2026, I want to share a few extra details about the Investor and Analyst Day we have coming up. It's set for October 6th, and we'll be streaming it online as well as holding it in person at our Emeryville headquarters. The team is putting together a session they expect to be productive, and the agenda includes presentations from management, a look at some of our partner programs, and time for Q&A. Anyone who can attend in person will also get to see a demo of our xPloration technology and take part in lab tours. You will additionally have the chance to meet other members of our team face to face, among them Amechi, for those who have not yet met him, who will also share more regarding our plans for the xPloration platform; an online link has been provided in our press release for further information and participation details regarding the investor and analyst event. Beyond that event, we have several technical presentations scheduled in the months ahead concerning our OmniUltra technology, for which we are delighted to witness continued robust adoption and also to see some significant new application possibilities; on the lower portion of this slide, a few of those forthcoming talks on OmniUltra have been highlighted by us. To give you some context, we introduced Ultra toward the end of last year. It's the first and only transgenic chicken that produces antibodies with ultralong CDRH3s—a structural trait usually seen in antibodies from cows. These ultralong CDRH3s are designed to access binding pockets that other antibodies or modalities can't reach, which could open up new therapeutic possibilities. They may also play a part in things like serving as building blocks for multi-specifics, acting as binders for CAR-T and radiopharma treatments, and functioning as in vivo-generated peptides. One of our scientific leaders, Dr. Christel Iffland, will give a few talks on OmniUltra in Europe in late October and early November. With that, I will hand the call back to Kurt to discuss our financials. Kurt?

Kurt Gustafson

executive
#4

Thanks, Matt. As Matt pointed out, this quarter was a solid one, powered by gains across our partner portfolio. Turning to slide 14, I'll begin with quarterly revenue, which came in at $13.4 million, versus $3.9 million during the second quarter of 2025. That rise came mainly from greater milestone revenue, which mirrors how our partners' clinical programs are progressing. We also recorded more xPloration sales in this quarter, with two instruments sold, while service revenue ticked up somewhat thanks to several new ion channel agreements that were signed late in the prior year and earlier in this one. Slide 15 covers our year-to-date revenue through June 30th, 2026. Revenue overall climbed to $27.8 million, up from $8.1 million across the equivalent stretch of 2025. Much like the quarterly numbers, growth here was chiefly fueled by more milestone revenue. Keep in mind that milestone revenue tends to swing quite a bit between quarters. In the prior year, milestone revenue skewed toward the second half, whereas this year it leans toward the front end. Now on slide 16, you'll find operating expense for the quarter. We're still carrying out our plan to run things efficiently while putting suitable money into our technology platforms. Even though the figures appear level versus the prior year, I should point out that the prior year's number contained a one-time net gain of roughly $2 million tied to selling an ion channel asset. That lowered operating expense in the prior year on a net basis. Looking at it from a genuine operating angle, the chart makes clear that both R&D and G&A expense fell nicely, reflecting operational efficiencies we've realized. Slide 17 lays out operating expenses for the year to date. Beginning with the other expense line, I've already covered the gain from the prior year that lowered operating expense, and earlier in this year we recorded a non-cash write-off during the first quarter. Together, those two items distort the overall operating expense comparison. Again, viewed from a genuine operating angle, if you look at R&D and G&A costs, the efficiencies we've driven in the business become apparent. Slide 18 presents our P&L for both the quarter and the year to date. Since I've already taken you through the revenue and OpEx figures on earlier slides, I'll concentrate on the bottom line. Net loss for the second quarter of 2026 narrowed to $5.9 million, or $0.05 per share. That's against a net loss of $15.9 million, or $0.15 per share, in the comparable period a year ago. Net loss for the year-to-date stretch fell similarly, landing at $13.6 million, or $0.11 per share, compared with a net loss of $34.1 million, or $0.32 per share, in the earlier period. Among the metrics we rolled out this year is a non-GAAP figure we call cash costs and operating expense. On slide 19, there's a reconciliation showing how our GAAP operating expense ties to our cash operating expense. That cash figure strips out the big non-cash items: depreciation, stock-based compensation, and amortization of intangibles. The table makes clear that roughly 35%-40% of what we spend on operations isn't cash, and that's the reason we think this cash metric gives a truer picture of our actual operating expense. Broadly speaking, over the past couple of years we've been pushing our cash costs lower. Keep in mind these comparisons carry that one-time gain from the prior year period that I brought up earlier. If you set that gain aside, both cash cost and operating expenses would have posted a steeper decline versus the prior year. Now to the balance sheet, slide 20: the quarter closed with $52 million in cash. That cash balance rose during the second quarter thanks to milestone payments we received. The accounts receivable figure reflects certain milestones reached in the second quarter that haven't been paid yet. We still hold the view that, given the cash flows we anticipate, the company has ample capital to carry out our strategy. Slide 21 has our updated 2026 financial guidance, which captures the strong second quarter performance along with how we see the rest of the year. Besides raising guidance for revenue and our year-end cash balance, we've narrowed the ranges on all these metrics too. For 2026 total revenue, we've lifted the range to $32 million-$36 million. That increase stems mainly from more milestone achievements during the second quarter; we're tightening the OpEx guidance range slightly and now expect 2026 GAAP operating expense between $84 million-$88 million, with cash operating expense between $51 million-$55 million. On cash: with revenue expected to be higher, we now expect to finish 2026 with cash and cash equivalents between $37 million-$41 million. Our effective tax rate across the full year should stay at roughly 0% due to the valuation allowance we record. On to slide 22. We've presented this slide for the last couple of quarters, and I figured I'd show it once more this quarter to give historical context and call out the guidance changes we're making now. As the slide shows, our three-year financial metrics are getting better. Cash use especially stands out. We expect revenue to grow substantially in 2026 compared with 2025, while cash operating expense should stay within a tight band, which pushes overall cash use down. We're still in a stretch where milestones largely drive revenue, and those can swing a lot from one quarter to the next, but our portfolio of partner programs keeps expanding and moving forward; that ought to generally push milestone revenue up. This year, the advantages of our business model are starting to show. Our milestone base keeps getting bigger. As partner programs move closer to possible approvals, we anticipate royalties will make up an increasingly larger share of our revenue streams. Along with our scalable infrastructure, we believe these elements will fuel the company's long-term profitability. Having said that, I'd now like to turn the call over to questions. Operator?

Matt Hewitt

analyst
#5

Good afternoon, everyone, and congratulations on a strong quarter. Perhaps first, congrats on the xPloration sales. Since you currently have a handful of them in the ecosystem, what's the utilization picture looking like? Is it beginning to increase, and regarding the sales pipeline, how is that developing — might it be uneven in the near term, or are you beginning to see a rhythm that could lead to steadier sales there?

Matt Foehr

executive
#6

Yes, Matt, thank you. I'll share a few thoughts, then I'll ask Amechi to weigh in too. Broadly speaking, our enthusiasm about the xPloration opportunity hasn't changed. Actually, as our understanding deepens, so does our confidence that this may serve as a significant addition to what we do in antibodies. At this point, we aren't providing a breakdown of the various revenue sub-components, though we anticipate xPloration will drive our revenue growth both this year and in the future. Securing two unit sales during the quarter was excellent news, and we now have four deployed in the field. It's likely still a bit soon to discuss consumables and related matters, but given Amechi's background, I'd like to ask him to share his perspective too. Clearly, he's heavily involved alongside the team and engaging with our customers as well.

Amechi Nwachuku

executive
#7

Thanks. Thanks. From everything I've observed across life sciences tools and capital equipment, platforms that stand apart — such as xPloration — can genuinely generate multiple, lasting sources of revenue: placements of instruments, recurring use of consumables and reagents, plus software and service. As for xPloration, we continue to assess the complete commercial opportunity and the optimal way to seize it. Perhaps at our coming Analyst and Investor Day, we'll look to reveal more about our thinking there — regarding the platform, the market potential, and its strategic part.

Matt Hewitt

analyst
#8

That's excellent. So perhaps I could ask something else. Clearly, things have improved a great deal when it comes to financing for pharma and biotech, and I wonder if that's something you're already noticing, or does a delay usually happen? And if there is one, when do you think some of that money could begin coming your way? Thanks.

Matt Foehr

executive
#9

Yeah, Matt, appreciate it. Let me offer a comment. Over the past 2 years, I'd say we've observed quite strong expansion in partners and programs once attrition is accounted for. From the angle of the kinds of bets our larger partners are making, I do perceive those effects. I'd say we're fortunate to have technologies that amount to a truly significant and lasting competitive edge. Through our partner ecosystem and the strong ties we maintain with those partners, we gain solid insight into not just their current activities, but also their future direction and similar matters. Since our technologies are quite distinctive, we can see where they'd like to concentrate in terms of targets and indications. Broadly speaking, I'd say the major companies are placing larger bets; they're pursuing larger indications that have considerable unmet need. We're also noticing a rise in, let me put it this way, smaller partners; we pointed to a few new relationships, or rather new licenses, that were signed during this quarter. EnRosa Therapeutics, which I want to call out, is a preclinical stage, venture-funded biotech firm working on selective pathogenic cytotoxic T-cell depleters that use bispecific antibodies. A truly seasoned team, genuinely compelling science, and an excellent fit with what we do. I think that illustrates a newly well-capitalized, emerging preclinical stage participant that's now moving forward aggressively. Then on the larger end, clearly, we brought argenx on board this quarter. Clearly a worldwide leader in both research and commercial terms, truly driving a new era in immunology, so it's exciting to have them as a partner and to see activity there increasing too. I hope that provides some color on what we're observing.

Matt Hewitt

analyst
#10

Yeah, no, that is quite useful. Thanks a lot.

Brendan Smith

analyst
#11

Excellent. Appreciate you all fielding our questions, and congratulations on the headway being made here. Perhaps as a fast follow-up first regarding xPloration. I simply want to verify and confirm how we ought to be viewing the effect on margins there. It's good to see the revenues flowing in. Just curious how we should be thinking about, and what your expectations are concerning, the relative effect on margins, as that product scales up across the quarters ahead. On a separate note, I wanted to ask, when it comes to your conversations with potential partners and investment discussions, has OmniUltra been a major point of emphasis? Perhaps what sort of feedback has come back, and how are you thinking about its relative contribution, perhaps toward new partner deals compared with some of the other offerings, over roughly the next 12, 18 months?

Kurt Gustafson

executive
#12

Yeah. Well, thanks for those questions, Brendan. Perhaps I'll address the first one regarding margins, and then Matt, you can weigh in. When it comes to margins, I believe what we've communicated to you is that we have what I'd describe as quite strong margins on the instrument and even stronger margins on the consumables. As far as margins go, you might observe some fluctuation from quarter to quarter, simply because of the mix that comes through. There's additionally some service revenue that forms a piece of that too. I won't claim that this quarter or the patterns you're witnessing represent a trend you ought to concentrate on moving forward, since it will shift somewhat purely depending on the mix we encounter in any given quarter. It's a solid margin, and we anticipate that continuing.

Matt Foehr

executive
#13

Yes. Brendan, regarding what you asked about OmniUltra, it's been very encouraging to see that this product is genuinely creating fresh markets and fresh possibilities for our company. I'd describe it as something that generates a great deal of incoming interest, and OmnidAb does the same, and I believe both are positioned well to make significant contributions to this industry, with OmniUltra offering dual modality, covering antibodies as well as peptides. Naturally, that brings in plenty of inquiries, and we will of course keep showcasing some of our newest data and applications. OmnidAb likewise has significant potential applications, such as brain shuttling and multi-specifics. Each of them can be applied in what I'd refer to as truly high-value fields, for instance ion channels and GPCRs and similar areas. There's considerable interest in high-value targets for these. We've been quite happy with the conversations and with getting new programs and new partners signed up, and we anticipate being able to share more on that once partners begin discussing data down the road.

Michael King

analyst
#14

Thanks for fielding this, everyone. Congratulations on the advancement and the higher outlook. I've got 2 questions, both on the financial side. First, despite the bump to revenue guidance, you still have that $20+ million shortfall between what you spend and what you expect to bring in. I'm curious how we ought to frame the path to narrowing it. Will you keep attempting to fund it yourselves? Might you need to pull capital from somewhere external? Or do you figure on pushing up the worth of each contract?

Matt Foehr

executive
#15

Yes. Mike, I'll jump in, and Kurt can chime in too. We're feeling quite positive about our position and the direction the business is taking. As we said, the milestones tied to our late-stage assets total $340 million. There's a genuinely strong stream of fresh deal interest coming our way, and we feel great about the situation we're in and the position we hold. Kurt, perhaps you'd like to offer additional nuance or finer points.

Kurt Gustafson

executive
#16

Okay, Mike — we entered the year holding $54 million in cash, and when you look at where our cash stood at year-end, using the midpoint of that range, we're burning roughly $15 million over this year. From that perspective alone, the runway looks quite extended. If you pull back and consider how we've been expanding on the revenue side, it's the clinical milestones that are fueling the majority of that top-line growth at present. Looking ahead, we believe royalties will start coming into play. Like I said, that clinical base keeps expanding and maturing, and as that occurs, it triggers more and more milestones. We absolutely anticipate top-line growth, and that revenue essentially falls through to the bottom line, since we've discussed the scalable infrastructure we've built. We're keeping a firm grip on costs, so you won't see those scale alongside revenue, and the extra revenue coming in flows down to the bottom line. That, in my view, is how we bridge the gap, but as Matt mentioned, we're feeling very confident about our current position.

Michael King

analyst
#17

If I could try to sum up, you're saying that inside the company you have strong insight into how likely it is that some of these later-stage collaborations — Immunovant and Teva, and so on — will succeed, and you believe those can cover most of the shortfall, close that shortfall. Is that accurate?

Matt Foehr

executive
#18

What I would say as well, Mike, is simply take a look at how the clinical stage programs have advanced, the clinical stage programs that everyone can see, correct?

Michael King

analyst
#19

Yes.

Matt Foehr

executive
#20

That really reflects how strongly our partners believe in these programs. It's great to witness. This year, we've seen a steady stream of new items moving into the clinic. We anticipate more will be going into the clinic. Yeah, we feel really good about our current position.

Michael King

analyst
#21

All right. That's a valid point. I'll drop it. On a similar note, as we reconsider our model over a longer period and how we approach our analysis, I'm just wondering what your sense is regarding the speed at which deals will come in. Do you view this as a model that speeds up as time passes, or one that remains constant while delivering more value? How ought we to consider the OmniAb model across a 3- to 5-year timeframe?

Matt Foehr

executive
#22

Yes, Mike, clearly you consider our history, and from that angle, I'll begin by noting our basis in technologies that are strongly differentiated, quite innovative, long-lasting, and provide a significant edge over competitors. That's the thing that attracts partners. That's the thing that attracts programs. If you simply examine the past 2 years, which were a period when the entire industry confronted obstacles, we nonetheless expanded net of attrition, in both programs and partners, at quite an impressive rate. I believe that says a great deal about how distinctive our technologies are, and I believe it puts us in a very strong position going forward. We've also kept watching partners fulfill their role by advancing in the clinic, with new items moving into the clinic. We have several truly promising later-stage programs that partners characterize as pipeline-in-a-product style programs, where we hold downstream milestones and royalties. When you examine the model, milestones are essential. Clearly, those will keep increasing as time goes on. Once you begin to add royalties, for which we now enjoy more and more visibility as these items advance, that genuinely generates considerable strength in the model. Also remember that a number of our royalty agreements are tiered, which means our royalty percentage rises as revenue increases; that likewise contributes substantial strength to the model. So, those are just a few broad remarks that should prove useful.

Michael King

analyst
#23

All right, that answers it. I appreciate it — that clears things up. Thank you, Matt.

Stephen Willey

analyst
#24

Hello there, and good afternoon. I appreciate you letting us ask some things. I realize this particular deck doesn't include any of those figures, but I was wondering whether you might share a bit of detail regarding the way the count of preclinical efforts sitting after discovery has changed across the past 6 months, and also how you expect that specific category to grow between now and the close of the year. I'm simply attempting to understand—

Matt Foehr

executive
#25

Sure.

Stephen Willey

analyst
#26

how the clinical stage portfolio might expand in the months ahead. Thanks.

Matt Foehr

executive
#27

Yes, Steve, thank you. Yes, what we've kept seeing is, I'd put it, solid advancement, solid movement up through programs, and that applies both in what I'd call the discovery-to-preclinical stage, preclinical-to-phase I, phase I-to-phase II, phase II-to-phase III; growth in that area has kept looking solid, and what we observe makes us quite happy. Like we said, 4 new items have gone into the clinic during this year. We anticipate further additions during this year too, and those are candidates that would be moving from preclinical into phase I. There may be a span of time that candidates spend in the preclinical phase depending on the indication, depending on the kind of preclinical work that partners are requested to perform or must perform given how they deal with regulatory authorities. I should point out, though, that earlier during this year, guidance shifted somewhat regarding the preclinical work required for particular kinds of antibody programs that are going into the clinic for the first time. We view that as a possible long-term tailwind, particularly for some of our smaller partners. That provides a bit of detail on that.

Stephen Willey

analyst
#28

Okay, fine, thanks. That’s a solid question.

Matt Foehr

executive
#29

Thanks, Steve.

Analyst

analyst
#30

Hi, everyone. Michael is here in place of Puneet. Nice work on the beat-and-raise quarter. I wanted a little more detail on the guidance. It sounds as though you're suggesting only low single digits each quarter across the back half. How much of that reflects caution from your side, and how much comes from some kind of one-time factor we ought to know about in the front half? Clearly, the milestones matter. What do you expect in the back half?

Kurt Gustafson

executive
#31

Right. Michael, we won't go too deep into the revenue guidance. During my prepared remarks, I noted that for this year the milestones clearly serve as the primary growth engine for us at present, and those milestone achievements are weighted toward the early part of 2026. Nothing bad is going on with the remaining lines, whether xPloration, royalties, or service revenue. Actually, we had more or less stated that service revenue ought to perform even stronger in 2026 compared with 2025. That's about as far as I can go in assisting you with how to consider the back half of the year.

Analyst

analyst
#32

All right, that's helpful. For my next question, I was hoping you could shed some light on how much your portfolio is exposed to lab in the loop and the use of AI in antibody drug discovery. I'm aware you've pointed to some interest in that area coming from xPloration. Other tools companies have experienced notable growth in that space. What I'd like to know is how OmniAb takes advantage of that, and how much of an effect is it having on the business right now?

Matt Foehr

executive
#33

Yes. Michael, thank you. As people who track us carefully and are familiar with us understand, we strongly believe AI delivers advantages and acts as a tailwind for the sector in numerous ways. Those who've been paying attention know that we introduced our OmniDeep brand more than three years back, and OmniDeep is a collection of in silico tools — AI and ML in silico tools — integrated across our technology stack. Correct? Everything begins with top-quality input data, and that data is genuinely proprietary, unavailable anywhere else, which matters greatly when pursuing novel targets. Our transgenic animals are truly the central piece of that. We came up with the phrase biological intelligence years back, and that sits at the very heart of it, particularly when pursuing novel targets. One more essential piece is the xPloration platform — its capacity to produce enormous volumes of data within a very short window. I'd describe that as both hits and misses, correct? That's what makes the xPloration platform valuable. With our OmniDeep platform, we obviously supply that to deep learning models so they can propose new hits, and that can act as training data and create greater efficiency. We genuinely view all of this as a possible tailwind for us, and from many different angles. I've noted before that at the latest AACR meeting, I believe it was BioCentury that reported its analysts had found more than 175 oncology targets that were previously untracked, correct? Completely new oncology targets being revealed for the first time. That kind of development. You begin to consider how our animals, engineered with human immune systems, can help steer that — I'd call it an ocean of potential zones where a therapeutic might be sought. Combining that with xPloration and AI and ML tools, I believe, is extremely powerful. We're enthusiastic about where the industry is heading on that front; we believe xPloration can be instrumental in producing large data sets, and we truly think the overall pace of drug discovery is speeding up, and that will be a positive development.

Analyst

analyst
#34

Excellent. Many thanks.

Matt Foehr

executive
#35

Excellent. Thanks, operator. I want to express my gratitude to each of you for being on this call today, as well as for the questions you've raised and the engagement you've shown. I'd also like to give thanks to the folks on our team at OmniAb for the hard work they keep putting in on our innovative platforms and for keeping their attention on our customers. The people on our team take considerable pride in what they do, and we appreciate that. We're eager to talk about our third-quarter financial results a few months from now, and until then, we'll be present at a number of investor conferences coming up, among them the H.C. Wainwright Conference in New York City in the middle of September. It's exciting for us to host our Investor and Analyst Day right here on October 6th, and we hope to see some of you at that time. Thanks once more. Have a wonderful day.

Operator

operator
#36

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 131,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to OmniAb, Inc. earnings transcripts and 131,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.